AIM-HI Accelerator Fund shared a post on LinkedIn:
“AIM-HI portfolio company Clasp Therapeutics has announced encouraging preclinical data for CLSP-5282, a first-in-class KRas-directed T-cell engager (TCE) designed to target KRas G12V-mutant cancers.
The data demonstrated:
- Potent mutation-specific tumor killing
- Strong anti-tumor activity in preclinical models
- Enhanced activity in tumors resistant to KRas inhibitors
- Potential for rational dual-KRas targeting
Clasp plans to submit an Investigational New Drug (IND) application in 2026, marking an important step toward clinical development.
Congratulations to the Clasp team on this milestone.”
Other articles about AIM-HI Accelerator Fund on OncoDaily.